Authors
Keywords
Abstract
This manuscript outlines the efficient synthesis of Acridine, a novel tyrosine kinase inhibitor designed to target oncogenic pathways. The synthesis involves a strategic combination of nitration, amination, condensation, and reduction steps to afford the final compound. Acridine exhibits a unique structure, incorporating a 3-nitroacridin-9-yl moiety, positioning it as a promising candidate for further investigation in cancer therapy.
The abstract provides a concise overview of the synthesis of Acridine, a novel tyrosine kinase inhibitor designed to target oncogenic pathways. The strategic synthesis involves nitration, amination, condensation, and reduction steps, yielding a compound with a 3-nitroacridin-9-yl moiety. Acridine emerges as a promising candidate for cancer therapy, exhibiting unique structural features poised for inhibition of tyrosine kinase pathways.
The synthesis of Acridine commenced with the nitration of a carefully selected acridine derivative, introducing a crucial nitro functionality. Subsequent amination and condensation reactions facilitated the incorporation of an amino group, forming the core structure of Acridine through condensation with phenylbutane-sulfonamide. The reduction of the nitro group resulted in the final product, Acridine, characterized by ^1H NMR, ^13C NMR, mass spectrometry, and HPLC.
Acridine's unique structure, featuring a 3-nitroacridin-9-yl moiety, positions it as a promising tyrosine kinase inhibitor for targeted cancer therapy. The abstract concludes by highlighting the potential of Acridine in inhibiting oncogenic pathways, paving the way for further studies to explore its biological activity, selectivity, and therapeutic applications in cancer treatment.